Calcineurin inhibitors

Calcineurin inhibitors are a group of immunosuppressants that reduce immune system activity. They are used in both dermatology and organ transplant care to control inflammation and prevent immune-related damage. These medications are available in various dosage forms, including oral capsules and tablets, topical ointments and creams, intravenous (IV) solutions, and eye drops.

Calcineurin inhibitors are medications that suppress the immune system by targeting specific immune cells. They are classified as immunosuppressants because they reduce the activity of T cells, a type of white blood cell involved in inflammation and immune reactions.

By limiting immune system overactivity, calcineurin inhibitors help reduce inflammation in skin conditions like eczema and atopic dermatitis. They are also essential in preventing immune attacks on transplanted organs such as the kidney, liver, or heart. These medications are widely used in healthcare and require careful monitoring.

The mechanism of action of calcineurin inhibitors involves blocking the calcium-dependent protein phosphatase, calcineurin. Calcineurin normally activates T lymphocytes by triggering the release of cytokines that promote inflammation.

When calcineurin is inhibited, T cells are less active and produce fewer inflammatory signals. This reduces immune responses in the skin and throughout the body. By limiting cytokine release, calcineurin inhibitors help control inflammation without the skin-thinning effects seen with corticosteroids.

This targeted action explains why topical calcineurin inhibitors are often used for sensitive areas such as the face, neck, and skin folds.

Calcineurin inhibitors include both topical and systemic medications.

Topical calcineurin inhibitors (TCI)

These medications are primarily used in dermatology for inflammatory skin conditions. Topical tacrolimus (Protopic) and pimecrolimus (Elidel) are FDA-approved for eczema treatment, including moderate atopic dermatitis and severe eczema in adults and children over certain ages. They are also used off-label for vitiligo, seborrheic dermatitis, and other skin conditions.

Systemic calcineurin inhibitors

These medications are taken orally or by injection and are used for immune suppression.

• Cyclosporine (Neoral, Sandimmune).

• Tacrolimus (Prograf, Astagraf XL, Envarsus XR).

• Voclosporin (Lupkynis).

These are commonly used after an organ transplant to prevent rejection. They are also used for autoimmune conditions such as lupus nephritis, rheumatoid arthritis, and ulcerative colitis in selected cases.

Calcineurin inhibitors are used for a variety of immune-related conditions.

Dermatology and skin conditions like eczema, including atopic dermatitis, when topical steroids are not effective or not appropriate. They are useful for long-term management and for sensitive skin areas. These medications are also used for psoriasis, vitiligo, and certain inflammatory skin conditions.

Organ transplant and immune suppression to reduce the risk of organ transplant rejection by suppressing immune responses that target the transplanted organ. They may also be used after a bone marrow transplant.

Autoimmune and inflammatory diseases, for autoimmune diseases such as lupus nephritis, ulcerative colitis, and severe inflammatory conditions that do not respond to other treatment options.

Side effects depend on whether the medication is used topically or systemically.

Common side effects of topical calcineurin inhibitors include:

• Burning or stinging at the application site.

• Itching or redness.

• Increased sensitivity to sunlight.

Systemic calcineurin inhibitors have a higher risk of adverse effects, including:

• Kidney problems.

• High blood pressure.

• Increased risk of infection.

• Headache or tremors.

Long-term use of systemic calcineurin inhibitors may increase the risk of lymphoma and skin cancer due to immune suppression.

These are not all of the possible side effects of calcineurin inhibitors. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Although these medications are generally well-tolerated and safe, there are certain warnings, precautions, and drug interactions you should be aware of.

Warnings

Before starting calcineurin inhibitors, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including:

• Kidney disease.

• A weakened immune system.

• A history of skin cancer or lymphoma.

• Ongoing skin infection at the treatment site.

Topical calcineurin inhibitors should not be applied to infected skin.

Boxed Warning

Topical calcineurin inhibitors carry an FDA boxed warning about a possible increased risk of lymphoma and skin cancer. This warning is based on animal studies and rare case reports. Current evidence from dermatology clinical trials suggests that when used as directed, TCIs are safe for appropriate patients.

Systemic calcineurin inhibitors also carry boxed warnings about the increased risk of developing serious infections and malignancies that could require hospitalization and death.

Contraindications

Calcineurin inhibitors may not be appropriate for people with severe immune suppression or active infections. Systemic forms should be avoided or used cautiously in patients with significant kidney disease.

Drug interactions

When calcineurin inhibitors are taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

Liver enzyme inhibitors, such as macrolide antibiotics or azole antifungals, can increase the toxicity of calcineurin inhibitors.

Liver enzyme inducers such as anticonvulsants and HIV medications can reduce the efficacy of calcineurin inhibitors.

NSAIDs (ibuprofen, naproxen) and other nephrotoxic medications can increase the risk of kidney injury when used with calcineurin inhibitors.

Additive effects with other immunosuppressants.